Top Markets
Coin of the day
Brainstorm Cell Therapeutics Inc. Brainstorm Cell Therapeutics Inc.

Brainstorm Cell Therapeutics Inc.

BCLI
株式のランク #31761
Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to... Brainstorm Cell Therapeutics Inc. (BCLI) is a biotechnology firm dedicated to the development and commercialization of personalized, autologous cellular therapies. These innovative treatments are specifically designed to address neurodegenerative diseases. At the heart of its strategy is the proprietary NurOwn cell therapy platform. This platform employs sophisticated cell culture techniques to prompt mesenchymal stem cells, derived from the patient's own bone marrow, to produce high concentrations of neurotrophic factors. This process aims to regulate neuroinflammatory and neurodegenerative disease mechanisms, bolster the survival of neurons, and ultimately enhance neurological function. NurOwn is currently undergoing significant clinical development, having completed a Phase III clinical trial for Amyotrophic Lateral Sclerosis (ALS). Additionally, it has successfully advanced through Phase II clinical trials for both progressive multiple sclerosis and Alzheimer's disease, with potential applications being explored for other neurodegenerative conditions. To support its therapeutic pipeline, the company has established a manufacturing partnership with Catalent for NurOwn. Incorporated in 2000, the company initially operated as Golden Hand Resources Inc. before adopting the name Brainstorm Cell Therapeutics Inc. in November 2004. Its corporate headquarters are situated in New York, New York.
株価
$1.10
最終同期: 2026-08-17
時価総額
$12.14M
変化(1日)
11.11%
変化(1年)
77.42%
US
取引 Brainstorm Cell Therapeutics Inc. (BCLI)

カテゴリー

Brainstorm Cell Therapeutics Inc.(BCLI)の配当利回りの履歴
Brainstorm Cell Therapeutics Inc.(銘柄コード: BCLI)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Brainstorm Cell Therapeutics Inc.(BCLI)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)